Abstract:AIM:To investigate the clinical effect of intravitreal conbercept on wet age-related macular degeneration(wAMD)and polypoidal choroidal vasculopathy(PCV).
METHODS: Sixteen patients(16 eyes)with wAMD and 5 patients(5 eyes)with PCV, both clinical diagnosed, were enrolled. All patients were treated with intravitreous conbercept.Additional treatments were administered if needed. Best corrected visual acuity(BCVA), central retinal thickness(CRT)and choroidal thickness(CT)were measured periodically.
RESULTS:The mean injection times at 6mo was 2.93±0.27. The mean BCVAs were 0.87±0.52 at baseline and 0.74±0.43 at 6mo, which the difference was not statistically significant. The mean CRT significantly improved from 352.24±131.82 to 251.73±69.41μm at 6mo(P<0.01). The mean CT reduced from 331.93±115.35 to 304.72±104.59μm(P<0.05).
CONCLUSION:Intravitreal conbercept can keep the visual acuity stable, reduce the retinal thickness and is safe on treating wAMD and PCV.
